Vyndamax (tafamidis)

A daily pill that works by holding the transthyretin protein together in its normal shape, preventing it from breaking apart and forming the amyloid deposits that damage the heart.

Tafamidis sticks to the TTR (transthyretin) protein and holds it in its correct shape. When TTR misfolds, it clumps together and damages organs like the heart. This drug acts like a glue that keeps TTR stable and folded correctly, preventing the harmful clumps from forming.

In the main heart trial, side effects were reported about as often with tafamidis as with placebo, and similar numbers of people stopped treatment because of a side effect (7% on the 80 mg dose versus 6% on placebo). Tafamidis may harm an unborn baby based on animal studies, so tell your doctor if you are or could become pregnant.

Tafamidis is a pill taken by mouth once a day, with or without food. In the U.S., the dose is Vyndamax 61 mg (one 61-mg capsule) once daily. The label also lists Vyndaqel 80 mg (four 20-mg capsules) once daily, but Pfizer stopped supplying Vyndaqel in the U.S. at the end of 2025. The 2 are not interchangeable milligram for milligram, and capsules should be swallowed whole. Treatment continues as long as the patient is benefiting and tolerating it well.

Yes, Tafamidis (Vyndamax) is FDA approved (2019) for the treatment of ATTR Amyloidosis and Wild-Type ATTR Cardiac Amyloidosis.

Vyndaqel (tafamidis meglumine) comes as a 20 mg capsule, while Vyndamax (tafamidis free acid) comes as a 61 mg capsule. Four Vyndaqel capsules (80 mg) are bioequivalent to one Vyndamax capsule (61 mg), meaning they achieve the same drug levels in the body. Pfizer stopped supplying Vyndaqel in the United States at the end of 2025, so Vyndamax (1 capsule once a day) is now the only tafamidis option in the U.S. If you were taking Vyndaqel, switching to Vyndamax will likely require a new prescription and a new prior authorization from your insurance.

Tafamidis stabilizes the TTR protein in its normal tetrameric (four-part) shape, preventing it from dissociating into monomers that misfold and form amyloid deposits. Gene silencing therapies like patisiran and vutrisiran take a different approach by sharply lowering how much TTR the liver makes (vutrisiran lowered blood TTR by about 83% in its trial). Tafamidis preserves TTR's normal biological functions (like transporting vitamin A and thyroid hormone), while gene silencers lower TTR along with its normal jobs, which is why people taking them are advised to take a daily vitamin A supplement.

The ATTR-ACT Phase 3 trial enrolled 441 patients with ATTR cardiomyopathy and showed that tafamidis reduced all-cause mortality by 30% and cardiovascular-related hospitalizations by 32% compared to placebo over 30 months. This was the first clinical trial to demonstrate that a drug could improve survival in ATTR cardiomyopathy, leading to FDA approval in May 2019.

Yes. Tafamidis is approved for both hereditary (variant) and wild-type ATTR cardiomyopathy. Wild-type ATTR-CM, where the normal TTR protein misfolds due to aging, is increasingly recognized as an underdiagnosed cause of heart failure in older adults, particularly men over 65. Tafamidis stabilizes both mutant and wild-type TTR protein.

In the United States, tafamidis is FDA-approved specifically for ATTR cardiomyopathy. In Europe, it was first approved in 2011 for hereditary ATTR with polyneuropathy. While tafamidis may help slow nerve damage progression by preventing new amyloid deposits, it does not reverse existing nerve damage. Patients with primarily neurological symptoms may also be candidates for gene silencing therapies like patisiran or vutrisiran.

In the ATTR-ACT trial, the survival benefit of tafamidis became apparent after about 18 months of treatment. Patients may not feel immediate improvement in symptoms, and some may initially continue to decline before the treatment effect becomes measurable. This is because tafamidis prevents new amyloid deposition but does not clear existing deposits. Consistent daily use over the long term is essential.